NAD+ injection vs IV
NAD+ injection vs IV: route, evidence, time and cost
NAD+ injections and IV infusions are not interchangeable evidence categories. An IV infusion delivers a product into a vein in a supervised setting; the online plans audited here are marketed as at-home subcutaneous injections. The small human pilot often cited for NAD+ used a six-hour IV infusion and measured metabolites. It did not test the effectiveness, safety or equivalent dose of the current home-injection plans. Price comparisons also need separate data because this site has audited injection subscriptions, not a representative market of clinic IV sessions.
Puts the popular route comparison next to the exact evidence and commerce boundaries instead of treating delivery speed as proof of better outcomes. It is a bounded source review, not a systematic review or individual medical advice.
IV route
Delivered into a vein in a supervised setting
Online injection route
Marketed for subcutaneous use at home
Human evidence cited here
One small six-hour IV metabolite pilot
What is the difference between NAD+ injection and IV therapy?
An IV infusion enters a vein over a defined session. The online injection plans on this site are subcutaneous prescriptions intended for home administration. That changes the setting, product handling and route.
The routes should have separate evidence and price records. A molecule with the same name is not enough to establish equivalent exposure or outcomes.
Does IV research prove that NAD+ injections work?
No. The cited pilot measured blood and urine metabolites during and after a six-hour IV infusion in a very small group of men. It did not test at-home subcutaneous subscriptions.
The study also did not establish longer life or broad symptom improvement. Transferring its biochemical result to a different route would overstate the evidence.
Which route is safer?
The current source set does not establish a universal safer route. IV administration has clinical-setting and line-related considerations, while a home injection adds storage, handling, administration and pharmacy-quality questions.
FDA has reported reactions linked to unsuitable ingredients in sterile compounded NAD+ injectables. That alert reinforces the need to identify the product and pharmacy rather than naming a route winner.
Which route costs less?
Longevity Ranked has sourced recurring prices and commitments for several online injection plans. It has not collected a representative set of clinic IV prices, session durations and required fees, so this page does not publish a false apples-to-apples winner.
Compare the complete bill, supplied quantity, visit or facility fees and the number of planned administrations. A monthly headline and a per-session IV price answer different questions.
Approved partner · source-audited provider
PeterMD
PeterMD NAD+: injection and capsule routes.
PeterMD lists $369 for an 8 to 10-week injection supply and capsule terms from $125.65 for 30 days. Route, formulation and quantities differ, so these are separate decisions.
Partner link; we may earn a commission. Editorial order and findings do not change.
Partner links track referrals through Katalys/Revoffers. Broad placements use the longevity catalog; product buttons use the exact approved destination. This relationship does not change comparison order or review findings. Refund and auto-bill policy. Checked September 22, 2026.
Where can I compare current NAD+ providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Sprout Health’s NAD+ injection referral offer excludes California.
Which sources support this answer?
Sources were checked September 21, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.